<ul>
<li>3 支高股息股票，现在收入，未来增长</li>
</ul>
<p>百时美施贵宝（NYSE:BMY - 免费报告）- Zacks Research 的投资分析师在 6 月 26 日星期三向客户和投资者发布的研究报告中，提高了他们对百时美施贵宝股票 2024 年第四季度每股收益（EPS）的预估。Zacks Research 分析师 E. Bagri 现在预计这家生物制药公司本季度每股收益为 1.70 美元，高于他们之前的预估 1.69 美元。百时美施贵宝当前全年收益的共识预估为每股 0.58 美元。Zacks Research 还预测了百时美施贵宝 2026 财年的每股收益为 6.25 美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 警报：</p>
<p>BMY 已成为许多其他报告的话题。StockNews.com 在一份报告中将百时美施贵宝的评级从 “强烈买入” 调降为 “买入”，巴克莱在 4 月 26 日星期五的一份报告中将百时美施贵宝的目标股价从 51.00 美元降至 43.00 美元，并设定了 “等权重” 评级。Societe Generale 在 3 月 11 日星期一的一份研究报告中，将百时美施贵宝的评级从 “买入” 调降为 “持有”。BMO Capital Markets 在 4 月 26 日星期五的一份研究报告中，将百时美施贵宝的目标股价从 55.00 美元降至 48.00 美元，并为该公司设定了 “市场表现” 评级。最后，富国银行将百时美施贵宝的目标股价从 51.00 美元上调至 52.00 美元，并在 4 月 18 日星期四的一份研究报告中为该股设定了 “等权重” 评级。一位研究分析师对该股票进行了卖出评级，十五位分析师给出了持有评级，四位分析师给出了买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标股价为 60.00 美元。</p>
<p><strong>阅读我们关于百时美施贵宝的最新报告</strong></p>
<h2>百时美施贵宝价格表现</h2>
<p>NYSE BMY 股票周一开盘价为 41.53 美元。该公司市值为 841.9 亿美元，市盈率为-13.40，PEG 比率为 14.21，β值为 0.43。百时美施贵宝过去十二个月的最低价为 39.63 美元，最高价为 65.38 美元。该公司的速动比率为 0.99，流动比率为 1.11，负债股本比率为 2.99。该公司的 50 天移动平均价为 42.97 美元，200 天移动平均价为 48.11 美元。</p>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）上次发布财报是在 4 月 25 日星期四。这家生物制药公司报告本季度每股亏损 4.40 美元，超过了每股亏损 4.53 美元的共识预估 0.13 美元。百时美施贵宝的净资产回报率为 8.83%，净利润率为-13.50%。该公司本季度的营收为 118.7 亿美元，高于 114.5 亿美元的共识预估。与去年同期相比，该季度公司的营收增长了 4.7%。</p>
<h2>机构投资者对百时美施贵宝的看法</h2>
<p>对该公司的持股情况最近发生了变化。Northwest Financial Advisors 在第四季度购入了百时美施贵宝股票，价值 27000 美元。ESL Trust Services LLC 在第一季度购入了百时美施贵宝股票，价值约 27000 美元。Accordant Advisory Group Inc 在第一季度购入了百时美施贵宝股票，价值约 31000 美元。Pacific Capital Wealth Advisors Inc.在第四季度购入了百时美施贵宝股票，价值约 34000 美元。最后，Turtle Creek Wealth Advisors LLC 在第四季度购入了百时美施贵宝股票，价值 40000 美元。目前，76.41% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>百时美施贵宝宣布股息</h2>
<p>该公司最近宣布了季度股息，将于 8 月 1 日星期四支付。股东记录日期为 7 月 5 日星期五，将支付 0.60 美元的股息。该股息的除息日期为 7 月 5 日星期五。这代表了每年 2.40 美元的股息和 5.78% 的收益率。百时美施贵宝的派息比率为-77.42%。</p>
<h2>百时美施贵宝公司简介（获取免费报告）</h2>
<p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、市场、分销和销售生物制药产品。它提供用于血液病学、肿瘤学、心血管病学、免疫学、纤维化和神经科学疾病的产品。该公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者的中风/全身栓塞风险，并用于 DVT/PE 的治疗；Opdivo，用于各种抗癌适应症，包括膀胱癌、血液癌、CRC、头颈癌、RCC、HCC、肺癌、黑色素瘤、MPM、胃癌和食道癌；Pomalyst/Imnovid，用于多发性骨髓瘤；Orencia，用于活动性类风湿关节炎和银屑病性关节炎；以及 Sprycel，用于费城染色体阳性慢性髓细胞白血病的治疗。</p>
<h2>特色文章</h2>
<ul>
<li>我们喜欢的五支股票，比百时美施贵宝更好</li>
<li>市值计算器：如何计算市值</li>
<li>Upwork 股票前景：尽管面临 Gen-AI 挑战，数字仍稳固</li>
<li>使用 MarketBeat 股息率计算器</li>
<li>瓦尔格林股票暴跌背后：投资者下一步该怎么做</li>
<li>宝洁 NYSE: PG 在摇摆的指引后回落</li>
<li>MarketBeat 周评 - 6/24 - 6/28</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。在发布之前，该故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 特朗普的逮捕是第一阶段（来自 Porter &amp; Company）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw"/></p>
<h2>现在是否值得投资$1,000 美元购买百时美施贵宝？</h2>
<p>在考虑购买百时美施贵宝之前，您可能想听听这个消息。</p>
<p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

百时美施贵宝

<p>摩根士丹利研究的投资分析师调高了百时美施贵宝 2024 年第四季度的每股收益预期。预计这家生物制药公司该季度每股收益为 1.70 美元。公司全年盈利的共识预期为每股 0.58 美元。百时美施贵宝 2026 财年的盈利预计为每股 6.25 美元</p>

<ul>
<li>3 High-Yield Dividend Stocks for Income Now and Growth Later</li>
</ul>
<div class="lb-trans"><ul>
<li>3 支高股息股票，现在收入，未来增长</li>
</ul>
</div><p>Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at Zacks Research increased their Q4 2024 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research report issued to clients and investors on Wednesday, June 26th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will earn $1.70 per share for the quarter, up from their prior estimate of $1.69. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $0.58 per share. Zacks Research also issued estimates for Bristol-Myers Squibb's FY2026 earnings at $6.25 EPS.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 免费报告）- Zacks Research 的投资分析师在 6 月 26 日星期三向客户和投资者发布的研究报告中，提高了他们对百时美施贵宝股票 2024 年第四季度每股收益（EPS）的预估。Zacks Research 分析师 E. Bagri 现在预计这家生物制药公司本季度每股收益为 1.70 美元，高于他们之前的预估 1.69 美元。百时美施贵宝当前全年收益的共识预估为每股 0.58 美元。Zacks Research 还预测了百时美施贵宝 2026 财年的每股收益为 6.25 美元。</p>
</div><p>Get <strong>Bristol-Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 警报：</p>
</div><p>BMY has been the topic of a number of other reports. StockNews.com downgraded Bristol-Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Thursday. Barclays dropped their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an &#34;equal weight&#34; rating on the stock in a report on Friday, April 26th. Societe Generale downgraded Bristol-Myers Squibb from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, March 11th. BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a &#34;market perform&#34; rating for the company in a research report on Friday, April 26th. Finally, Wells Fargo &amp; Company raised their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Thursday, April 18th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and an average target price of $60.00.</p>
<ul>
<li>Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore</li>
</ul>
<div class="lb-trans"><p>BMY 已成为许多其他报告的话题。StockNews.com 在一份报告中将百时美施贵宝的评级从 “强烈买入” 调降为 “买入”，巴克莱在 4 月 26 日星期五的一份报告中将百时美施贵宝的目标股价从 51.00 美元降至 43.00 美元，并设定了 “等权重” 评级。Societe Generale 在 3 月 11 日星期一的一份研究报告中，将百时美施贵宝的评级从 “买入” 调降为 “持有”。BMO Capital Markets 在 4 月 26 日星期五的一份研究报告中，将百时美施贵宝的目标股价从 55.00 美元降至 48.00 美元，并为该公司设定了 “市场表现” 评级。最后，富国银行将百时美施贵宝的目标股价从 51.00 美元上调至 52.00 美元，并在 4 月 18 日星期四的一份研究报告中为该股设定了 “等权重” 评级。一位研究分析师对该股票进行了卖出评级，十五位分析师给出了持有评级，四位分析师给出了买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标股价为 60.00 美元。</p>
</div><p><strong>Read Our Latest Report on Bristol-Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于百时美施贵宝的最新报告</strong></p>
</div><h2>Bristol-Myers Squibb Price Performance</h2>
<div class="lb-trans"><h2>百时美施贵宝价格表现</h2>
</div><p>Shares of NYSE BMY opened at $41.53 on Monday. The firm has a market cap of $84.19 billion, a P/E ratio of -13.40, a PEG ratio of 14.21 and a beta of 0.43. Bristol-Myers Squibb has a twelve month low of $39.63 and a twelve month high of $65.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a 50 day moving average of $42.97 and a 200 day moving average of $48.11.</p>
<ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><p>NYSE BMY 股票周一开盘价为 41.53 美元。该公司市值为 841.9 亿美元，市盈率为-13.40，PEG 比率为 14.21，β值为 0.43。百时美施贵宝过去十二个月的最低价为 39.63 美元，最高价为 65.38 美元。该公司的速动比率为 0.99，流动比率为 1.11，负债股本比率为 2.99。该公司的 50 天移动平均价为 42.97 美元，200 天移动平均价为 48.11 美元。</p>
</div><p>Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The company's revenue for the quarter was up 4.7% compared to the same quarter last year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）上次发布财报是在 4 月 25 日星期四。这家生物制药公司报告本季度每股亏损 4.40 美元，超过了每股亏损 4.53 美元的共识预估 0.13 美元。百时美施贵宝的净资产回报率为 8.83%，净利润率为-13.50%。该公司本季度的营收为 118.7 亿美元，高于 114.5 亿美元的共识预估。与去年同期相比，该季度公司的营收增长了 4.7%。</p>
</div><h2>Institutional Investors Weigh In On Bristol-Myers Squibb</h2>
<div class="lb-trans"><h2>机构投资者对百时美施贵宝的看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $27,000. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. Accordant Advisory Group Inc bought a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at approximately $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter worth about $34,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the 4th quarter valued at $40,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对该公司的持股情况最近发生了变化。Northwest Financial Advisors 在第四季度购入了百时美施贵宝股票，价值 27000 美元。ESL Trust Services LLC 在第一季度购入了百时美施贵宝股票，价值约 27000 美元。Accordant Advisory Group Inc 在第一季度购入了百时美施贵宝股票，价值约 31000 美元。Pacific Capital Wealth Advisors Inc.在第四季度购入了百时美施贵宝股票，价值约 34000 美元。最后，Turtle Creek Wealth Advisors LLC 在第四季度购入了百时美施贵宝股票，价值 40000 美元。目前，76.41% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>Bristol-Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百时美施贵宝宣布股息</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.78%. Bristol-Myers Squibb's payout ratio is -77.42%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 8 月 1 日星期四支付。股东记录日期为 7 月 5 日星期五，将支付 0.60 美元的股息。该股息的除息日期为 7 月 5 日星期五。这代表了每年 2.40 美元的股息和 5.78% 的收益率。百时美施贵宝的派息比率为-77.42%。</p>
</div><h2>Bristol-Myers Squibb Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>百时美施贵宝公司简介（获取免费报告）</h2>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、市场、分销和销售生物制药产品。它提供用于血液病学、肿瘤学、心血管病学、免疫学、纤维化和神经科学疾病的产品。该公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者的中风/全身栓塞风险，并用于 DVT/PE 的治疗；Opdivo，用于各种抗癌适应症，包括膀胱癌、血液癌、CRC、头颈癌、RCC、HCC、肺癌、黑色素瘤、MPM、胃癌和食道癌；Pomalyst/Imnovid，用于多发性骨髓瘤；Orencia，用于活动性类风湿关节炎和银屑病性关节炎；以及 Sprycel，用于费城染色体阳性慢性髓细胞白血病的治疗。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Bristol-Myers Squibb</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>Procter &amp; Gamble NYSE: PG Pulls Back After Shaky Guidance</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
</ul>
<div class="lb-trans"><h2>特色文章</h2>
<ul>
<li>我们喜欢的五支股票，比百时美施贵宝更好</li>
<li>市值计算器：如何计算市值</li>
<li>Upwork 股票前景：尽管面临 Gen-AI 挑战，数字仍稳固</li>
<li>使用 MarketBeat 股息率计算器</li>
<li>瓦尔格林股票暴跌背后：投资者下一步该怎么做</li>
<li>宝洁 NYSE: PG 在摇摆的指引后回落</li>
<li>MarketBeat 周评 - 6/24 - 6/28</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。在发布之前，该故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Trump’s arrest is phase one (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 特朗普的逮捕是第一阶段（来自 Porter &amp; Company）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8600&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Bristol-Myers Squibb right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 美元购买百时美施贵宝？</h2>
</div><p>Before you consider Bristol-Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买百时美施贵宝之前，您可能想听听这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol-Myers Squibb currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

分析师上调了百时美施贵宝（NYSE:BMY）2024 年第四季度的每股收益预期